Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

Autor: Mingqing Lu, Canping Huang, Liang Shen, Xiaoyong Tang, Yufang Zhu, Jiaming Lan, Shichao Li, Zhe Ding, Chunhua Wang, Gary Wong, Ji Zhang, Jianzhong Zhao, Ying Shen
Rok vydání: 2020
Předmět:
Male
0301 basic medicine
delayed
Epidemiology
severity
Disease
Antibodies
Viral
COVID-19 Testing
Drug Discovery
Child
Aged
80 and over
Immunoassay
medicine.diagnostic_test
biology
Articles
General Medicine
Middle Aged
Infectious Diseases
Severe progression
Disease Progression
Female
GICA
medicine.symptom
Antibody
Coronavirus Infections
Research Article
Adult
China
Adolescent
Pneumonia
Viral
030106 microbiology
Immunology
Real-Time Polymerase Chain Reaction
Microbiology
Virus
Betacoronavirus
Young Adult
03 medical and health sciences
Virology
medicine
Humans
Pandemics
Aged
Clinical Laboratory Techniques
SARS-CoV-2
business.industry
COVID-19
Specific igm
030104 developmental biology
Bronchoalveolar lavage
Antibody response
Immunoglobulin M
IgM antibody
Antibody Formation
biology.protein
Sputum
Parasitology
business
Zdroj: Emerging Microbes & Infections
article-version (VoR) Version of Record
ISSN: 2222-1751
DOI: 10.1080/22221751.2020.1766382
Popis: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread rapidly worldwide since it was confirmed as the causative agent of COVID-19. Molecular diagnosis of the disease is typically performed via nucleic acid-based detection of the virus from swabs, sputum or bronchoalveolar lavage fluid (BALF). However, the positive rate from the commonly used specimens (swabs or sputum) was less than 75%. Immunological assays for SARS-CoV-2 are needed to accurately diagnose COVID-19. Sera were collected from patients or healthy people in a local hospital in Xiangyang, Hubei Province, China. The SARS-CoV-2 specific IgM antibodies were then detected using a SARS-CoV-2 IgM colloidal gold immunochromatographic assay (GICA). Results were analysed in combination with sera collection date and clinical information. The GICA was found to be positive with the detected 82.2% (37/45) of RT-qPCR confirmed COVID-19 cases, as well as 32.0% (8/25) of clinically confirmed, RT-qPCR negative patients (4–14 days after symptom onset). Investigation of IgM-negative, RT-qPCR-positive COVID-19 patients showed that half of them developed severe disease. The GICA was found to be a useful test to complement existing PCR-based assays for confirmation of COVID-19, and a delayed specific IgM antibody response was observed among COVID-19 patients with severe progression.
Databáze: OpenAIRE
Externí odkaz: